MacroGenics grants Janssen Biotech license to preclinical MGD011; terminated
MacroGenics Inc. licensed Johnson & Johnson’s Janssen Biotech Inc. global rights to its preclinical antibody candidate MGD011 aimed at treating leukemias and lymphomas including B-cell malignancies.
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com